LEO Pharma, Thomas Hultsch
LEO Pharma appointed Thomas Hultsch as head of translational medicine. Hultsch has been set the task of building a new translational medicine group in Boston, US, as well as overseeing existing operations in the US and Europe.
Hultsch joins the company from Sanofi, where he held the position of senior medical director for translational medicine. Prior to this, he had worked as a VP for medical marketing for dermatology products at Galderma.
“At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that”, said Kim Kjoeller, EVP for global research and development at LEO Pharma.
The move follows the decision by LEO Pharma to bolster its dermatology division with the acquisition of Bayer’s dermatology unit, shortly followed by a deal to gain access to JW Pharmaceutical’s atopic dermatitis drug candidate.